TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06907615: A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Sponsor: Shanghai Henlius Biotech · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 243 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06907615 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06907615 Rescue Dossier →